The Oncobiology of the ProstateEdited By
- D.P. Wood, Department of Urology, Wayne State University, Detroit, MI, USA
- K.V. Honn, Department of Radiation Oncology, Wayne State University, Detroit, MI, USA
Prostate cancer (PCa) is the most common newly diagnosed cancer among men in the United States today. With the advent of the prostate-specific antigen (PSA) test, the number of newly diagnosed cases has increased tremendously. The rates of PCa have increased so dramatically over the last decade that the age-adjusted incidence rate of PCa is no greater than that for any other cancer among men in the United States. Although PCa rates have risen steadily since 1973, there has been a dramatic acceleration in the late 1980s which has been associated with the introduction and use of PSA for screening and early detection. There is now some evidence that the rates may be levelling off and even decreasing in some areas. After lung cancer, PCa is the leading cause of death due to cancer in men in the United States. Although PCa can occur in younger men, it is essentially a cancer of elderly men. The highest rates of PCa in the world occur among African-American men in the United States. African-Americans have higher rates than Caucasians at all age levels in the United States, and adjusting for social-economic status does not appear to account for this difference to any appreciable extent. There is no clear reason why PCa rates are so much greater among African-Americans compared with Caucasians in the United States. The reported rates in Africans are substantially lower than those of an African-American, suggesting that environmental factors have an influence on PCa. In spite of this substantial impact on our society. PCa remains a relatively understudied disease, with an essentially unknown etiology.
The reviews contained in this book are by no means exhaustive. We have, however, attempted to provide information regarding the pathology of prostate cancer, the status of diagnostic and prognostic markers, as well as a discussion of our understanding of the molecular basis for the disease. The biology of prostate cancer is covered with a discussion on the role of apoptosis in prostate cancer and the suggestion of it being the target for new therapeutic development, as well as the role played by integrins and angiogenesis. The status of current therapies, both hormonal and chemotherapy, are also discussed. This volume should provide a useful background for individuals wishing to commence an in-depth understanding of prostate cancer.
Advances in Oncobiology
Published: December 2000
- Contents. List of Contributors. Introduction (D.P. Wood, Jr. and K.V. Honn). Pathology of Prostate Cancer (D.J. Grignon and W.A. Sakr). Animal Model Systems for the Study of Prostate Cancer (M.L. Cher, J. Harb, and J. Nemeth). Tumor Markers for Prostate Cancer (X. Gao and K.V. Honn). Molecular Biology of Prostate Cancer: Tumor Suppressor Genes (X. Gao and K.V. Honn). Apoptosis and Prostate Cancer (K. Tang and K.V. Honn). Angiogenesis in Prostate Cancer (D. Nie and K.V. Honn). Molecular Progression of Prostate Cancer (S. Sirvastava and J.W. Moul). Biology of Prostate Cancer Bone Marrow Metastasis (J.A. Nemeth and M.L. Cher). Integrins in Prostate Cancer Metastasis (M. Trikha and K.V. Honn). Neoadjuvant Hormonal Therapy Prior to Radical Prostatectomy: Promises and Pitfalls (M.E. Gleave and S.L. Goldenberg). Current Management of Hormone-Refractory Prostate Cancer (O. Sartor and W.D. Figg). Index.